Abstract
Beata Smolarz1, Magdalena M. Michalska2, Dariusz Samulak2,3, Hanna Romanowicz1 and Luiza Wójcik1
1Laboratory of Cancer Genetics, Department of Clinical Pathology, Polish Mothers' Memorial Hospital-Research Institute, Lodz, Poland
2Department of Obstetrics and Gynaecology, Regional Hospital in Kalisz, Poland
3Cathedral of Mother’s and Child’s Health, Poznań University of Medical Sciences, Poznań, Poland
Correspondence to:
Beata Smolarz, email: [email protected]
Keywords: breast cancer; DNA repair; polymorphism; gene
Received: July 18, 2018 Accepted: December 27, 2018 Published: January 11, 2019
ABSTRACT
Aim: The aim of the study was to determine the relationship between single nucleotide polymorphisms (SNPs) of DNA repair genes and modulation of the risk of breast cancer. The following SNPs were analysed: XRCC1-Arg399Gln (rs25487), hMSH2-Gly322Asp (rs4987188), XRCC2-Arg188His (rs3218536), XPD- Lys751Gln (rs13181), RAD51--4719A/T (rs2619679) and RAD51--4601A/G (rs5030789).
Material and Methods: The study included n = 600 patients: 300 with breast cancer and 300 healthy controls. The HRM (High-Resolution Melter) technique was applied for polymorphism analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each genotype and allele.
Results: Statistically significant correlations were identified between four single nucleotide polymorphisms and the breast cancer risk: XRCC1-Arg399Gln, hMSH2-Gly322Asp, XPD- Lys751Gln and RAD51--4719A/T. Allele XRCC1-Gln (OR 6.37; 95% CI 4.86–8.35, p < .0001), hMSH2-Asp (OR 4.41; 95% CI 3.43–5.67, p < .0001), XPD -Gln (OR 2.56; 95% CI 2.02–3.25, p < .0001) and RAD51-T genes (OR 1.44; 95% CI 1.15–1.80, p = 0.002) strongly correlated with breast carcinoma. No relationship was observed between the studied polymorphisms and the cancer progression grade according to Scarf-Bloom-Richardson classification.
Conclusions: The results implies that polymorphisms of DNA repair genes may be associated with breast cancer occurrence.
INTRODUCTION
Breast cancer is the most frequent malignancy among women. Almost 16,000 of women in Poland are diagnosed annually with breast cancer; the death toll is greater than 5,000. It is estimated that this annual morbidity may rise up to 20 thousand women in 2020 [1, 2]. Following the latest data of Eurocare-5, a five-year survival is achieved by 71.6% of female patients in Poland vs. 82% of the mean European value. Regarding breast cancer, the percent of successful 5-year treatment outcomes in Poland is 10% lower than the EU average [3].
Breast cancer is characterized by the occurrence of different genetic changes in various genes [4–6]. Consequently, it is often not possible to give a straightforward answer to the question, whether these changes are more like causes or more like effects of the disease. If they are perceive as causes, it is justified to study if the genetic variability, observed in many populations and defined as genetic polymorphism, may in any way contribute to induction and/or development of malignant changes, including breast cancer. Breast cancer is a disease with significant genetic component, characterized by high cure rates with early diagnosis [7–9]. This is the reason why prophylactic examinations of subjects from the group with high genetic risk would facilitate early diagnosis, eventually leading to reduced mortality rates [7–9]. DNA repair is a part of the barriers, protecting from cancer forming mutations [10–12]. Following the results of studies, cancer diseases are driven by a compromised ability of DNA repair. Therefore, a set of alleles of repair protein encoding genes may largely define the individual abilities for DNA damage repair, as well as the susceptibility to tumor development. It is then important to learn the polymorphic variants of the genes, associated with DNA repairs, as well as with their degradation in their population. The single nucleotide polymorphisms (SNPs) may change the risk of cancer. SNPs may then be regarded as potential markers of carcinogenesis [13, 14].
In our research projects, we concentrated on an evaluation of the role of single nucleotide polymorphisms of DNA repair genes in the pathogenesis of breast cancer and in the prognosis of its further course. The primary objectives of our studies were to identify the SNPs, associated with the risk of breast cancer in women of the Polish population, and to estimate the risk of their carrier-state. The results of our studies may help better understand the molecular background of the disease formation and enable to evaluate the probability of its occurrence in specific subjects of the population. The polymorphisms of DNA repair genes were selected on the basis of literature data, which are highly suggestive of their correlations with cancers development.
The alternations in DNA mismatch repair (MMR) genes have been associated with cancers development. hMSH2 (MutS protein homolog 2) gene is involved in the MMR system [15]. Following data from the world literature, Gly322Asp polymorphism of hMSH2 gene may enhance the risk of malignancy in the colon or the stomach, as well as increase the incidence rate of lymphomas, anaemia and breast cancer [16–22]. Breast cancer risk may be correlated with endogenous oestrogens [23]. Oestrogens induce DNA damage by producing reactive oxygen species during metabolic reactions [24]. The oestrogens may bring about oxidative DNA defects, which are eliminated by the base excision repair (BER) and nucleotide excision repair (NER) systems. X-ray repair cross-complementing 1 (XRCC1) gene is involved in the BER pathway [25]. The Arg399Gln polymorphism of XRCC1 gene was selected on the basis of literature data, which are highly suggestive of its correlations with breast cancer development [26–28]. Oestrogens are genotoxic and influence carcinogenesis by the formation of bulky DNA adducts [29]. This type of damage is generally repaired by the nucleotide excision repair (NER) pathway. The XPD (the xeroderma pigmentosum group D) gene is involved in the NER pathway [30, 31]. The Lys751Gln (rs13181) polymorphism is one of the most widely studied genetic markers in XPD and its role in cancer development is evident [31]. Homologous recombination repair (HR) is also involved in the repair of DNA-protein cross-links in cooperation with NER. XRCC2 and RAD51 genes are key components of homologous recombination. According to literature data, the most frequently studied single nucleotide polymorphism of XRCC2 gene is Arg188His. It has been demonstrated in a number of reports that it plays a significant role in the development of neoplastic diseases, including breast cancer [32–35]. Earlier reports of many researchers, dealing with SNPs in RAD51 gene concentrated mainly on G135C and G172T polymorphisms at 5′ region, not subject of translation [36–40]. Our assumption was such that another genetic variability could act either additively or independently of the above-mentioned polymorphisms in 5′UTR region, what may help explain the role of RAD51 in breast cancer development. Our research was then oriented towards less investigated SNPs within RAD51 promoter gene: -4719A/T (rs2619679) and -4601A/G (rs5030789).
We examined 300 female patients with breast cancer and 300 healthy women for polymorphisms of the genes, belonging to: - the BER system XRCC1 gene - Arg399Gln polymorphism (rs25487), - the NER system XPD gene - Lys751Gln polymorphism (rs13181), - the MMR system hMSH2 gene - Gly322Asp (rs4987188), - the HR system XRCC2 gene Arg188His (rs3218536), RAD51 gene -4719A/T (rs2619679) and RAD51 gene -4601A/G (rs5030789).
RESULTS
In the studies on a series of 300 DNA samples from patients with breast cancer, originating from an ethnically homogenous population, we found a relationship of the studied polymorphisms with breast cancer occurrence (Table 1).
Table 1: Frequency distribution of the DNA repair genes genotypes/alleles in patients and controls, and the risk of breast cancer
Patients (n = 300) | Controls (n = 300) | |||||
|---|---|---|---|---|---|---|
XRCC1- Arg399Gln | Number | (%) | Number | (%) | OR (95% CI)a | p-value |
Arg/Arg | 34 | 11.33 | 66 | 22.00 | 1.00 Ref | |
Arg/Gln | 38 | 12.67 | 180 | 60.00 | 0.41 (0.23-0.70) | 0.0017 |
Gln/Gln | 228 | 76.00 | 54 | 18.00 | 8.19 (4.92-13.63) | <.0001 |
Arg | 106 | 17.67 | 312 | 52.00 | 1.00 Ref | |
Gln | 494 | 82.33 | 288 | 48.00 | 6.37 (4.86-8.35) | <.0001 |
hMSH2- Gly322Asp | Number | (%) | Number | (%) | OR (95% CI) | p-value |
Gly/Gly | 42 | 14.00 | 80 | 26.67 | 1.00 Ref | |
Gly/Asp | 51 | 17.00 | 177 | 59.00 | 0.54 (0.33-0.89) | 0.021 |
Asp/Asp | 207 | 69.00 | 43 | 14.33 | 9.16 (5.57-15.07) | <.0001 |
Gly | 135 | 22.5 | 337 | 56.17 | 1.00 Ref | |
Asp | 465 | 77.5 | 263 | 43.83 | 4.41 (3.43-5.67) | <.0001 |
XPD -Lys751Gln | Number | (%) | Number | (%) | OR (95% CI) | p-value |
Lys/Lys | 54 | 18.00 | 96 | 32.00 | 1.00 Ref | |
Lys/Gln | 70 | 23.33 | 120 | 40.00 | 1.03 (0.66-1.37) | 1.000 |
Gln/Gln | 176 | 58.67 | 84 | 28.00 | 3.72 (2.44-5.68) | <.0001 |
Lys | 178 | 29.67 | 312 | 52.00 | 1.00 Ref | |
Gln | 422 | 70.33 | 288 | 48.00 | 2.56 (2.02-3.25) | <.0001 |
XRCC2 -Arg188His | Number | (%) | Number | (%) | OR (95% CI) | p-value |
Arg/Arg | 72 | 24.00 | 80 | 26.67 | 1.00 Ref | |
Arg/His | 110 | 36.67 | 106 | 35.33 | 1.15 (0.76-1.74) | 0.571 |
His/His | 118 | 39.33 | 114 | 38.00 | 1.15 (0.76-1.73) | 0.571 |
Arg | 254 | 42.33 | 266 | 44.33 | 1.00 Ref | |
His | 346 | 57.67 | 334 | 55.67 | 1.08 (0.86-1.36) | 0.521 |
RAD51-4719A/T | Number | (%) | Number | (%) | OR (95% CI) | p-value |
A/A | 60 | 20.00 | 75 | 25.00 | 1.00 Ref | |
A/T | 126 | 42.00 | 150 | 50.00 | 1.05 (0.69-1.58) | 0.887 |
T/T | 114 | 38.00 | 75 | 25.00 | 1.90 (1.21-2.97) | 0.007 |
A | 246 | 41.00 | 300 | 50.00 | 1.00 Ref | |
T | 354 | 59.00 | 300 | 50.00 | 1.44 (1.15-1.80) | 0.002 |
RAD51-4601A/G | Number | (%) | Number | (%) | OR (95% CI) | p-value |
A/A | 78 | 26.00 | 87 | 29.00 | 1.00 Ref | |
A/G | 138 | 46.00 | 123 | 41.00 | 1.25 (0.84-1.84) | 0.305 |
G/G | 84 | 28.00 | 90 | 30.00 | 1.04 (0.67-1.59) | 0.920 |
A | 294 | 49.00 | 297 | 49.50 | 1.00 Ref | |
G | 306 | 51.00 | 303 | 50.50 | 1.02 (0.81-1.27) | 0.920 |
aCrude odds ratio (OR), 95% CI = confidence interval at 95%.
This study demonstrated that XRCC1-Gln/Gln genotype of Arg399Gln polymorphism was strongly correlated with breast cancer. The Gln/Gln homozygote increased the risk of cancer (OR 8.19). The Gln allele in those patients may be a risk factor for breast cancer (OR 6.37; 95% CI 4.86–8.35, p < .0001).
The studies successfully demonstrated that hMSH2- Asp/Asp (OR 9.16; 95% CI 5.57–15.07, p < .0001), XPD-Gln/Gln (OR 3.72; 95% CI 2.44–5.68, p < .0001) and RAD51-T/T genotypes (OR 1.90; 95% CI 1.21–2.97, p = 0.007) were strongly associated with an increased risk of breast cancer.
In addition, the alleles of hMSH2-Asp (OR 4.41; 95% CI 3.43–5.67, p < .0001), XPD -Gln (OR 2.56; 95% CI 2.02–3.25, p < .0001) and RAD51-T genes (OR 1.44; 95% CI 1.15–1.80, p = 0.002) are strongly correlated with breast cancer.
No statistically significant differences were observed in genotype frequencies of XRCC2 Arg188His polymorphism and RAD51 -4601A/G polymorphism between the group of patients and healthy controls. (Table 3).
Table 2: The characteristics of breast cancer cases (n = 300) and controls (n = 300)
Patients (n, %) | Controls (n, %) | |
|---|---|---|
Premenopausal | 112 (37.33) | 98 (32.67) |
Postmenopausal | 188 (62.67) | 202 (67.33) |
Body mass index (BMI ≥ 30 kg/m2) | ||
Yes | 140 (46.67) | 100 (33.33) |
No | 160 (53.33) | 200 (66.67) |
Hormone replacement therapy (HRT) | ||
Never | 114 (38.00) | 120 (40.00) |
Estrogen | 186 (62.00) | 180 (60.00) |
Hormone receptor status | ||
ER+ | 72 (24.00) | |
PR+ | 79 (26.33) | |
HER2+ | 110 (36.67) | |
ER+PR+HER2+ | 19 (6.33) | |
ER-PR-HER2 | 20 (6.67) | |
Histopathological grading | ||
G1 | 90 (30.00) | |
G2 | 110 (37.00) | |
G3 | 100 (33.00) | |
Tumor size grade | ||
T1 | 75 (25.00) | |
T2 | 135 (45.00) | |
T3 | 90 (30.00) | |
Lymph node status | ||
N0 | 90 (30.00) | |
N1 | 85 (28.33) | |
N2 | 75 (25.00) | |
N3 | 50 (16.67) |
Table 3: The refSNP and thermal conditions for HRM analysis
Polymorphism | refSNP | Primer sequence | Thermal conditions | |
|---|---|---|---|---|
XRCC1 | Arg399Gln | rs25487 | F 5′-TAAGGAGTGGGTGCTGGACT-3′ | PCR cycling (40 cycles) |
hMSH2 | Gly322Asp | rs4987188 | F 5′-GTTTTCACTAATGAGCTTGC-3′ | PCR cycling (40 cycles) |
XPD | Lys751Gln | rs13181 | F 5′-CCTCTGTTCTCTGCAGGAGGA-3′ | PCR cycling (40 cycles) |
XRCC2 | Arg188His | rs3218536 | F 5′-TGTAGTCACCCATCTCTCTGC-3′ | PCR cycling (40 cycles) |
RAD51 | -4719A/T | rs2619679 | F 5′-AGATAAACCTGGCCAACGTG-3′ | PCR cycling (40 cycles) |
RAD51 | -4601A/G | rs5030789 | F 5′-AGATAAACCTGGCCAACGTG-3′ | PCR cycling (40 cycles) |
No relationship was observed between the studied polymorphisms and the cancer progression grade acc. to Scarf-Bloom-Richardson classification.
We did not find any correlation between the studies polymorphic variants of the repair genes and tumour grade or the lymph node status. Neither was there any relationship demonstrated between the analysed polymorphisms and the status of the oestrogen (ER), progesterone (PR) or HER2 receptors. DNA repair genes polymorphisms were also unrelated to the patients age, Hormone replacement therapy (HRT), BMI or menopause status.
DISCUSSION
Our works fit in the general trend of studies, based on the commonly accepted and actual concept, assuming that the predisposition to cancers, including breast cancer, may be multigene in character, involving a relatively high number of low-penetration genes. In our studies, the groups of patients were ethnically uniform: female of the Polish origin, inhabitants of the Lodz Region.
We concentrated on an analysis of the relationship between Gly322Asp polymorphism of hMSH2 gene and breast cancer. We selected the gene for its documented participation in the pathogenesis of cancers. Following data from the world literature, Gly322Asp polymorphism of hMSH2 gene may enhance the risk of malignancy in the colon or the stomach, as well as increase the incidence rate of lymphomas, anaemia and breast cancer [41–43].
The Asp allele of Gly322Asp polymorphism was strongly correlated with breast cancer. The Gly322Asp polymorphism affected the tumour grade and size, as well as was associated with the lymph node status.
As literature data demonstrate DNA damages to be highly significant in the pathogenesis of breast cancer, especially those which require repair by homologous recombination [44, 45].
Therefore, our studies were continued in an analysis of subsequent polymorphisms in the gene, which encoded the protein, participating in repair by homologous recombination (RAD51).
We demonstrated a possible correlation of -4719A/T (rs2619679) and -4601A/G (rs5030789) polymorphisms of RAD51 repair gene with breast cancer. Earlier reports of many researchers, dealing with SNPs in RAD51 gene concentrated mainly on G135C and G172T polymorphisms at 5′ region, not subject of translation [46–49].
Since RAD51 participates in DNA repair, while also interacting with BRCA proteins, the mutations of which are often identified in breast cancer, the above-mentioned polymorphisms may be associated with a higher risk of this cancer development [50, 51].
It has been found, among others, that 135C variant may increase the risk of breast cancer in carriers of mutations in BRCA1 and BRCA2 genes, while no effects of 135C variant were observed on the morbidity level in women without the mutations. G135C polymorphism can modify the way of mRNA splicing, what, in turn, affects the protein functions or the effectiveness of translation [52].
Despite the abundance of results, there is still no unequivocal explanation of the role of RAD51 in cancer formation. Our assumption was such that another genetic variability could act either additively or independently of the above-mentioned polymorphisms in 5′UTR region, what may help explain the role of RAD51 in breast cancer development [46, 53, 54].
Our research was then oriented towards less investigated SNPs within RAD51 promoter gene: -4719A/T (rs2619679) and -4601A/G (rs5030789). We describe a group of 300 female patients with breast cancer, demonstrating that TT genotype of -4719A/T polymorphism and GG genotype of -4601A/G polymorphism of RAD51 gene was strongly correlated with breast cancer. Moreover, the AG heterozygote of -4601A/G polymorphism of RAD51 gene was more frequently observed in the first grade of the cancer disease (acc. to Scarf-Bloom-Richardson) than in stage II and III. None of the studied polymorphisms were associated with tumour size or the lymph node status.
The presented studies demonstrated that XRCC1–Gln/Gln and XPD-Gln/Gln genotypes were strongly associated with an increased risk of breast cancer.
We did not find any correlation between the studies polymorphic variants of the repair genes and tumour grade or tumour size or the lymph node status. Neither did we show any relationship of the analysed polymorphisms with the age of the patients, BMI, hormone replacement therapy or menopausal status.
In summation, the above presented studies contribute to a better knowledge of the molecular background of breast cancer. The results indicate DNA repair genes and their polymorphisms can be involved in the breast cancer formation process in the population of women in Poland. They may find practical application to improve the early diagnostics of cancer and thus to extend the survival rates of women with breast cancer.
MATERIALS AND METHODS
Patients
Blood samples were obtained from women with breast carcinoma (n = 300), treated at the Department of Department of Oncological Surgery and Breast Diseases, Institute of Polish Mothers Memorial Hospital. Blood specimens were collected from the patients by venipuncture before treatment. The criteria for patient participation in this study were as follows: histologically confirmed diagnosis of breast carcinoma, primary surgical resection of the breast without receiving prior immuno-, radio- or chemotherapy, absence of distant metastases. All the diagnosed tumors were graded by criteria of Scarf-Bloom-Richardson. The age of the patients ranged in from 48 to 84 years (the mean age 57.2 ± 10.12). 300 age-matched disease-free women were selected as controls (age range 49–80, mean age 55.26 ± 10.17). The full characteristics of the study group are presented in Table 2. The Local Ethic Committee approved the study and each patient gave a written consent (Approval number, 10/2012).
DNA isolation and genotyping
Genomic DNA was prepared using QIAamp DNA Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer instruction. Real-time PCR cycling and conditions and primers for HRM analysis of all the examined DNA repair SNPs are summarized in Table 3. CR amplification was performed with support of a Light Cycler® 480 High Resolution Melting Master Kit (Roche, Mannheim, Germany), according to the manufacturer’s recommendations. The HRM technique was carried out in a LightCycler® 96 (Roche, Mannheim, Germany) Thermocycler. A non-template control contained water, instead of genomic DNA, as a negative control. Additionally, positive controls (DNA samples with known genotype) were employed in each run of HRM analysis. All the control DNA samples were employed in each run of HRM analysis. The collected data were analyzed, using the LightCycler® 96 software version SW 1.1 (Roche, Mannheim, Germany). SNPs in DNA repair genes were selected using the public domain of the National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/snp (Bethesda, MD, USA). Primer3 software (http://frodo.wi.mit.edu/, Tartu, Estonia) was used for primers design.
Statistical analysis
Genotype and allele distributions were compared with those expected for a population in Hardy-Weinberg equilibrium (HWE) by using the Chi-square test. Genotype and allele frequencies in cases and controls were compared by χ2-test. Genotype and allele evaluation, regarding their relationship with a given feature, e.g., a risk for disease, was supported by an analysis of odds ratio (ORs) and 95% confidence intervals, calculated according to the logistic regression model. The wild type of genotype and allele was a reference group. P-values < 0.05 were considered significant.
Ethics approval
All the study participants gave a written informed consent. A formal consent was also issued by the Bioethical Committee of the Institute of the Polish Mother’s Memorial Hospital in Lodz (Approval number, No 10/2012).
Abbreviations
CI - Confidence interval; HRM - High resolution melting; HR - Homologous recombination repair; HWE - Hardy-Weinberg equilibrium; BER - Base excision repair; NER - Nucleotide excision repair; MMR - Mismatch repair; OR - Odds ratio; SNP - Single nucleotide polymorphism.
Author contributions
Conceived and designed the experiments: BS. Performed the experiments–case group: MMM, DS, HR. Case group design and collect: MMM, DS, HR. Performed the experiments–control group: BS. Analysed data: BS. Contributed reagents/materials/analysis tools BS. Contributed to the writing of manuscript: BS, LW. All authors approved the final manuscript.
ACKNOWLEDGMENTS
Authors acknowledge the financial support provided by the Institute of Polish Mother’s Memorial Hospital, Lodz, Poland, to conduct the study.
CONFLICTS OF INTEREST
Authors declare no conflicts of interest.
FUNDING
This work was supported by the Institute of Polish Mother’s Memorial Hospital, Lodz, Poland from the Statutory Development Fund.
REFERENCES
1. Leśniczak B, Krasomski G, Oszukowski P, Stetkiewicz T, Woźniak P. Incidence of and mortality from breast cancer among women in Poland in the years 2001-2010. Przegl Menopauz. 2014; 13:344–47. https://doi.org/10.5114/pm.2014.47990.
2. Radziszewska AU, Karczmarek-Borowska B, Grądalska-Lampart M, Filip AA. The incidence of breast cancer in population of young women from Podkarpackie province in 2002-2011. Contemp Oncol (Pozn). 2016; 20:176–84. https://doi.org/10.5114/wo.2016.60070.
3. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, Pierannunzio D, Santaquilani M, Trama A, Allemani C, Belot A, Buzzoni C, Lorez M, De Angelis R, and EUROCARE-5 Working Group. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer. 2015; 51:2104–19. https://doi.org/10.1016/j.ejca.2015.08.001.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458:719–24. https://doi.org/10.1038/nature07943.
5. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015; 26:1291–99. https://doi.org/10.1093/annonc/mdv022.
6. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC, Kleibeuker JH, Schaapveld M, de Vries EG. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002; 39:225–42. https://doi.org/10.1136/jmg.39.4.225.
7. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol. 2011; 45:46–52. https://doi.org/10.2478/v10019-010-0054-4.
8. Lukong KE. Understanding breast cancer - The long and winding road. BBA Clin. 2017; 7:64–77. https://doi.org/10.1016/j.bbacli.2017.01.001.
9. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000; 92:1126–35. https://doi.org/10.1093/jnci/92.14.1126.
10. Broustas CG, Lieberman HB. DNA damage response genes and the development of cancer metastasis. Radiat Res. 2014; 181:111–30. https://doi.org/10.1667/RR13515.1.
11. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet. 2015; 6:157. https://doi.org/10.3389/fgene.2015.00157.
12. Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J. DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol. 2016; 10:879–94. https://doi.org/10.1016/j.molonc.2016.02.005.
13. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer. 2004; 90:747–51. https://doi.org/10.1038/sj.bjc.6601574.
14. Shridhar K, Aggarwal A, Walia GK, Gulati S, Geetha AV, Prabhakaran D, Dhillon PK, Rajaraman P. Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: review of evidence to date. Oral Oncol. 2016; 61:146–51. https://doi.org/10.1016/j.oraloncology.2016.08.005.
15. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem. 2005; 74:681–710. https://doi.org/10.1146/annurev.biochem.74.082803.133243.
16. Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, Zidan J, Lancet D, Friedman E. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer. 2005; 114:58–73. https://doi.org/10.1002/ijc.20645.
17. Hu F, Li D, Wang Y, Yao X, Zhang W, Liang J, Lin C, Ren J, Zhu L, Wu Z, Li S, Li Y, Zhao X, et al. Novel DNA variants and mutation frequencies of hMLH1 and hMSH2 genes in colorectal cancer in the Northeast China population. PLoS One. 2013; 8:e60233. https://doi.org/10.1371/journal.pone.0060233.
18. Zhou JN, Wang DQ, Song L, Li SP, Ding JH, Ma GJ, Chen SQ, Zhang XM. Association of IVS10+12G>A polymorphism in hMSH2 gene with colorectal cancer. [Article in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010; 27:579–83.
19. Sud R, Wells D, Talbot IC, Delhanty JD. Genetic alterations in gastric cancers from British patients. Cancer Genet Cytogenet. 2001; 126:111–19. https://doi.org/10.1016/S0165-4608(00)00397-6.
20. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K. Polymorphism in the hMSH2 gene (gIVS 12-6T—>C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet. 2003; 147:71–74. https://doi.org/10.1016/S0165-4608(03)00185-7.
21. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, Holowaty EJ, Kohler BA, Wiklund T, Pukkala E, Roman E, Morgan GJ, Allan JM. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003; 9:3012–20.
22. Poplawski T, Zadrozny M, Kolacinska A, Rykala J, Morawiec Z, Blasiak J. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treat. 2005; 94:199–204. https://doi.org/10.1007/s10549-005-4793-7.
23. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011; 76:812–15. https://doi.org/10.1016/j.steroids.2011.02.029.
24. Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010; 44:479–96. https://doi.org/10.3109/10715761003667554.
25. Hanssen-Bauer A, Solvang-Garten K, Akbari M, Otterlei M. X-ray repair cross complementing protein 1 in base excision repair. Int J Mol Sci. 2012; 13:17210–29. https://doi.org/10.3390/ijms131217210.
26. Chen XP, Wen HF, Zhang F, Xu WH, Ma ZC, Fu SM. Assessment of the Link between XRCC1 Arg399Gln Polymorphism and Breast Cancer: a Meta-Analysis in a Single Ethnic Group. Clin Lab. 2017; 63:725–31. https://doi.org/10.7754/Clin.Lab.2016.161023.
27. Bu T, Liu L, Sun Y, Zhao L, Peng Y, Zhou S, Li L, Chen S, Gao Y. XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: a meta-analysis of 10846 cases and 11723 controls. PLoS One. 2014; 9:e86086. https://doi.org/10.1371/journal.pone.0086086.
28. Sanjari Moghaddam A, Nazarzadeh M, Noroozi R, Darvish H, Mosavi Jarrahi A. XRCC1 and OGG1 Gene Polymorphisms and Breast Cancer: A Systematic Review of Literature. Iran J Cancer Prev. 2016; 9:e3467.
29. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene. 2002; 21:8949–56. https://doi.org/10.1038/sj.onc.1206096.
30. Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, Cooper PK, Tainer JA. XPD helicase structures and activities: insights into the cancer and aging phenotypes from XPD mutations. Cell. 2008; 133:789–800. https://doi.org/10.1016/j.cell.2008.04.030.
31. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002; 17:463–69. https://doi.org/10.1093/mutage/17.6.463.
32. Zhai M, Wang Y, Jiang MF. Arg188His polymorphism in the XRCC2 gene and the risk of ovarian cancer: a meta-analysis. Genet Mol Res. 2015; 14:10808–15. https://doi.org/10.4238/2015.September.9.19.
33. Zhang Y, Wang H, Peng Y, Liu Y, Xiong T, Xue P, Du L. The Arg188His polymorphism in the XRCC2 gene and the risk of cancer. Tumour Biol. 2014; 35:3541–49. https://doi.org/10.1007/s13277-013-1468-6.
34. Qureshi Z, Mahjabeen I, Baig R, Kayani M. Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev. 2014; 15:10225–29. https://doi.org/10.7314/APJCP.2014.15.23.10225.
35. Smolarz B, Makowska M, Samulak D, Michalska MM, Mojs E, Wilczak M, Romanowicz H. Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women. Clin Exp Med. 2015; 15:151–57. https://doi.org/10.1007/s10238-014-0284-7.
36. Kayani MA, Khan S, Baig RM, Mahjabeen I. Association of RAD 51 135 G/C, 172 G/T and XRCC3 Thr241Met gene polymorphisms with increased risk of head and neck cancer. Asian Pac J Cancer Prev. 2014; 15:10457–62. https://doi.org/10.7314/APJCP.2014.15.23.10457.
37. Pelttari LM, Kiiski JI, Ranta S, Vilske S, Blomqvist C, Aittomäki K, Nevanlinna H. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. Springerplus. 2015; 4:92. https://doi.org/10.1186/s40064-015-0880-3.
38. Zhang BB, Wang DG, Xuan C, Sun GL, Deng KF. Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls. Fam Cancer. 2014; 13:515–26. https://doi.org/10.1007/s10689-014-9729-0.
39. Gresner P, Gromadzinska J, Polanska K, Twardowska E, Jurewicz J, Wasowicz W. Genetic variability of Xrcc3 and Rad51 modulates the risk of head and neck cancer. Gene. 2012; 504:166–74. https://doi.org/10.1016/j.gene.2012.05.030.
40. Lieber MR, Karanjawala ZE. Ageing, repetitive genomes and DNA damage. Nat Rev Mol Cell Biol. 2004; 5:69–75. https://doi.org/10.1038/nrm1281.
41. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, Antill YC, Thibodeau SN, Casey G, Gallinger S, Marchand LL, Newcomb PA, Haile RW, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013; 34:490–97. https://doi.org/10.1002/humu.22262.
42. Wu S, Chen J, Ji Y, Liu Y, Gao L, Chen G, Shen K, Huang B. Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis. Exp Ther Med. 2011; 2:1193–98. https://doi.org/10.3892/etm.2011.336.
43. Bansidhar BJ. Extracolonic manifestations of lynch syndrome. Clin Colon Rectal Surg. 2012; 25:103–10. https://doi.org/10.1055/s-0032-1313781.
44. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010; 4:255–66. https://doi.org/10.1016/j.molonc.2010.04.001.
45. Sekhar D, Pooja S, Kumar S, Rajender S. RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls. Sci Rep. 2015; 5:11588. https://doi.org/10.1038/srep11588.
46. Michalska MM, Samulak D, Romanowicz H, Smolarz B. Single Nucleotide Polymorphisms (SNPs) of RAD51-G172T and XRCC2-41657C/T Homologous Recombination Repair Genes and the Risk of Triple- Negative Breast Cancer in Polish Women. Pathol Oncol Res. 2015; 21:935–40. https://doi.org/10.1007/s12253-015-9922-y.
47. Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger T, Eeles RA, Peretz T. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer. 2004; 90:2002–05. https://doi.org/10.1038/sj.bjc.6601837.
48. Smolarz B, Zadrożny M, Duda-Szymańska J, Makowska M, Samulak D, Michalska MM, Mojs E, Bryś M, Forma E, Romanowicz-Makowska H. RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women. Pol J Pathol. 2013; 64:39–43. https://doi.org/10.5114/pjp.2013.34602.
49. Hosseini M, Houshmand M, Ebrahimi A. RAD51 polymorphisms and breast cancer risk. Mol Biol Rep. 2013; 40:665–68. https://doi.org/10.1007/s11033-012-2105-y.
50. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 1999; 59:1752s–56s.
51. Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res. 2005; 65:11384–91. https://doi.org/10.1158/0008-5472.CAN-05-2156.
52. Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2001; 10:955-60.
53. Zhou GW, Hu J, Peng XD, Li Q. RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011; 125:529–35. https://doi.org/10.1007/s10549-010-1031-8.
54. Wang W, Li JL, He XF, Li AP, Cai YL, Xu N, Sun SM, Wu BY. Association between the RAD51 135 G>C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls. PLoS One. 2013; 8:e75153. https://doi.org/10.1371/journal.pone.0075153.
